Allergan (NYSE:AGN) updated its first quarter earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of $3.20-3.40 for the period, compared to the Thomson Reuters consensus estimate of $3.71. The company issued revenue guidance of $3.5-3.6 billion, compared to the consensus revenue estimate of $3.75 billion.Allergan also updated its FY18 guidance to $15.25-16.00 EPS.
Several brokerages have recently weighed in on AGN. Royal Bank of Canada reaffirmed an outperform rating and set a $250.00 target price (down from $277.00) on shares of Allergan in a research note on Thursday, October 19th. They noted that the move was a valuation call. JPMorgan Chase & Co. set a $275.00 target price on Allergan and gave the stock a buy rating in a research note on Sunday, October 22nd. Wells Fargo & Co set a $245.00 target price on Allergan and gave the stock a buy rating in a research note on Friday, January 5th. Credit Suisse Group set a $214.00 target price on Allergan and gave the stock a buy rating in a research note on Tuesday, December 19th. They noted that the move was a valuation call. Finally, Mizuho downgraded Allergan from a buy rating to a neutral rating and set a $193.00 target price for the company. in a research note on Thursday, October 19th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. The stock presently has an average rating of Buy and an average price target of $227.56.
Shares of Allergan (AGN) opened at $165.00 on Tuesday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 1.18. Allergan has a 12-month low of $160.07 and a 12-month high of $256.80. The company has a market capitalization of $57,370.00, a P/E ratio of -7.30, a P/E/G ratio of 1.27 and a beta of 1.19.
Allergan (NYSE:AGN) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.74 by $0.12. Allergan had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm had revenue of $4.33 billion during the quarter, compared to analysts’ expectations of $4.28 billion. During the same period in the previous year, the business earned $3.90 earnings per share. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. analysts predict that Allergan will post 16.27 EPS for the current fiscal year.
In other news, Chairman Brent L. Saunders purchased 4,600 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The stock was purchased at an average cost of $164.74 per share, for a total transaction of $757,804.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Meury sold 11,807 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. Insiders have purchased 17,630 shares of company stock valued at $2,890,057 over the last quarter. 0.36% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.thestockobserver.com/2018/02/06/allergan-agn-releases-q1-earnings-guidance.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.